Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.49 |
| ▸ | GMPS | P49915 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 3/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.47 |
| ▸ | GAPDH | P04406 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932845 | 0.92 | ADORA3 (0.49) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL13269151 | 0.91 | ADORA2A (0.48) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL62485 | 0.91 | ADORA3 (0.48) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL27765322 | 0.91 | ADORA3 (0.48) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL13269063 | 0.90 | ADORA3 (0.46) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL13269086 | 0.90 | ADORA3 (0.48) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL1434125 | 0.90 | ADORA3 (0.48) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL4541363 | 0.90 | ADORA3 (0.48) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL13269127 | 0.90 | ADORA3 (0.48) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL13834595 | 0.89 | ADORA3 (0.46) | ADORA3ADORA2AGMPSPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575973-B1 | SUBSTITUTION DERIVATIVES OF N SP 6 SP -BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AV CR V V I (CZ) | 2017-08-23 | — | — | EP | claimed |
| US-20150231167-A1 | TREATMENT OF HEMATOLOGICAL NEOPLASMS | THOMAS JEFFERSON UNIVERSITY | 2015-08-20 | — | — | US | claimed |
| US-20150209379-A1 | TREATMENT OF PROSTATE CANCER AND HEMATOLOGIC NEOPLASMS | THOMAS JEFFERSON UNIVERSITY (US) | 2015-07-30 | — | — | US | claimed |
| CN-102625653-B | Methods for vegetative propagation of grass plants | TREEFREE BIOMASS SOLUTIONS INC | 2015-05-20 | — | — | CN | claimed |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-02-21 | — | — | US | claimed |
| EP-2511283-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2012-10-17 | — | — | EP | claimed |
| US-20120196825-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM | SUPPORTIVE THERAPEUTICS AG (CH) | 2012-08-02 | — | — | US | claimed |
| CN-102625653-A | Methods for vegetative propagation of grass plants | TREEFREE BIOMASS SOLUTIONS INC | 2012-08-01 | — | — | CN | claimed |
| US-8119614-B2 | Substitution derivatives of N6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2012-02-21 | — | — | US | claimed |
| CN-101602786-A | N 6-substituted adenosines derivative, its method for making and pharmaceutical composition and purposes | INST MATERIA MEDICA CAMS (CN) | 2009-12-16 | — | — | CN | claimed |
| US-6677154-B2 | PREPARTION OF GROWTH NUTRIENT FOR PLANTS; OBTAIN PLANT, REMOVE STEMS, PROPAGATE IN TISSUE CULTURE | GIELIS JOHAN (BE) | 2004-01-13 | — | — | US | claimed |
| US-20020169140-A1 | Combination therapy for reduction of toxicity of chemotherapeutic agents | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | claimed |
| WO-2002069949-A2 | COMBINATION THERAPY FOR REDUCTION OF TOXYCITY OF CHEMOTHERAPEUTIC AGENTS | PRENDERGAST PATRICK T (IE) | 2002-09-12 | — | — | WO | claimed |
| EP-0755255-A4 | TREATMENT OF TOXOPLASMOSIS | RES CORP TECHNOLOGIES INC (US) | 2002-07-24 | — | — | EP | claimed |
| US-20020086425-A1 | MICROPROPAGATION, SYNTHETIC SEEDS AND GERMPLASM STORAGE OF BAMBOOS | GIELIS JOHAN (BE) | 2002-07-04 | — | — | US | claimed |
| WO-2000053727-A1 | MICROPROPAGATION, SYNTHETIC SEEDS AND GERMPLASM STORAGE OF BAMBOOS | GIELIS JOHAN (BE) | 2000-09-14 | — | — | WO | claimed |
| WO-1998036636-A2 | METHOD FOR GENERATING EMBRYOGENIC CELL CULTURES FOR THE PRODUCTION OF BANANAS (MUSA SPP.) | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 1998-08-27 | — | — | WO | claimed |
| EP-0755255-A1 | TREATMENT OF TOXOPLASMOSIS | UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) | 1997-01-29 | — | — | EP | claimed |
| WO-1996018398-A1 | TREATMENT OF TOXOPLASMOSIS | THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-06-20 | — | — | WO | claimed |
| EP-0355825-A2 | Viral treatment system | Prendergast, Patrick T. (IE) | 1990-02-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209379-A1 | TREATMENT OF PROSTATE CANCER AND HEMATOLOGIC NEOPLASMS | MTAP, DPYD, PNP | ADORA3 56/4885ADORA2A 73/4885GMPS 35/4885 |
| US-20150231167-A1 | TREATMENT OF HEMATOLOGICAL NEOPLASMS | ABL1, AMPD3, AMPD2 | ADORA3 27/4885ADORA2A 11/4885GMPS 47/4885 |
| US-20120196825-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM | MRE11, XPA, MPL | ADORA3 389/4885ADORA2A 299/4885GMPS 88/4885 |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885GMPS 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.